Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states

Journal of the American Pharmacists Association

Volumn 57, Issue 2, 2017, Pages S19-S27.e4

  Green, Traci C ^a   Case, Patricia ^a   Fiske, Haley ^a   Baird, Janette ^a   Cabral, Shachan ^a   Burstein, Dina ^a   Schwartz, Victoriana ^a   Potter, Nathan ^a   Walley, Alexander Y ^a   Bratberg, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ADULT; ANALGESIA; ARTICLE; CAREGIVER; CHRONIC PAIN; CLINICAL PRACTICE; COMMUNITY; COMPARATIVE STUDY; CONSUMER; CONSUMER ATTITUDE; DATA SYNTHESIS; DRUG DEPENDENCE TREATMENT; DRUG SAFETY; FEMALE; FUTUROLOGY; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MASSACHUSETTS; MEDICAL SOCIETY; OPIATE ADDICTION; PERSONAL EXPERIENCE; PHARMACIST; PHARMACIST ATTITUDE; PHARMACY; PHARMACY SCHOOL; PRESCRIPTION; QUALITATIVE RESEARCH; RHODE ISLAND; RISK REDUCTION; SEMI STRUCTURED INTERVIEW; STIGMA; THEMATIC ANALYSIS; HEALTH PERSONNEL ATTITUDE; INFORMATION PROCESSING; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; PSYCHOLOGY; SOCIAL STIGMA; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; CAREGIVERS; CHRONIC PAIN; COMMUNITY PHARMACY SERVICES; FOCUS GROUPS; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; NALOXONE; OPIOID-RELATED DISORDERS; PHARMACISTS; PROFESSIONAL ROLE; RHODE ISLAND; SOCIAL STIGMA; YOUNG ADULT;

EID: 85028716059     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2017.01.013     Document Type: Article

References (46)

1. Mueller, S.R., Walley, A.Y., Calcaterra, S.L., et al. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus 36:2 (2015), 240–253.
2. Rudd, R.A., Aleshire, N., Zibbell, J.E., et al. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep 64:50-51 (2016), 1378–1382.
3. Rudd, R.A., Seth, P., Felicita, D., et al. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep 65:5051 (2016), 1445–1452.
4. Gladden, R.M., Martinez, P., Seth, P., Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths—27 states, 2013-2014. MMWR Morb Mortal Wkly Rep 65:33 (2016), 837–843.
5. Peterson, A.B., Gladden, R.M., Delcher, C., et al. Increases in fentanyl-related overdose deaths—Florida and Ohio, 2013-2015. MMWR Morb Mortal Wkly Rep 65:33 (2016), 844–849.
6. National Center for Health Statistics, NCHS factsheet. 2016, data on drug-poisoning deaths, Atlanta.
7. Boscarino, J.A., Rukstalis, M., Hoffman, S.N., et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:10 (2010), 1776–1782.
8. Sporer, K.A., Strategies for preventing heroin overdose. BMJ 326:7386 (2003), 442–444.
9. Sporer, K.A., Acute heroin overdose. Ann Intern Med 130:7 (1999), 584–590.
10. Gutstein, H., Akil, H., Opioid analgesics. Hardman, J., (eds.) Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 2006, McGraw-Hill, New York, 547–550.
11. Walley, A.Y., Xuan, Z., Hackman, H.H., et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ, 346, 2013, f174.
12. Bird, S.M., McAuley, A., Perry, S., et al. Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction 111:5 (2016), 883–891.
13. Seal, K.H., Thawley, R., Gee, L., et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 82:2 (2005), 303–311.
14. Coffin, P.O., Behar, E., Rowe, C., et al. Nonrandomized intervention study of naloxone coprescription for primary care patients receiving long-term opioid therapy for pain. Ann Intern Med 165:4 (2016), 245–252.
15. Green, T.C., Dauria, E.F., Bratberg, J., et al. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J, 12, 2015, 25.
16. Executive Office of Health and Human Services, Dispensing of naloxone by standing order: dispensing naloxone memo. Available at: http://www.mass.gov/eohhs/gov/departments/dph/programs/hcq/dhpl/pharmacy/dispensing-of-naloxone-by-standing-order-.html Accessed August 30, 2016.
17. Singer, M., Baer, H.A., Scott, G., et al. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep 113:Suppl (1998), 181–189.
18. Janulis, P., Pharmacy nonprescription syringe distribution and HIV/AIDS: a review. J Am Pharm Assoc (2003) 52:6 (2012), 787–797.
19. Cotten-Oldenburg, N.U., Carr, P., DeBoer, J.M., et al. Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999. J Acquir Immune Defic Syndr 27:2 (2001), 183–192.
20. Hayney, M.S., Influenza vaccine: basis for expanded pharmacy-based immunization services. J Am Pharm Assoc (2003) 44:3 (2004), 411–413.
21. Wang, T.W., Agaku, I.T., Marynak, K.L., et al. Attitudes toward prohibiting tobacco sales in pharmacy stores among U.S. adults. Am J Prev Med 51:6 (2016), 1038–1043.
22. Lopez-Trigo, P., Khanfar, N.M., Alameddine, S., et al. Banning tobacco sales at the retail pharmacy: natural evolution of drug store as responsible health provider or effective marketing strategy?. Health Mark Q 32:4 (2015), 382–393.
23. Corelli, R.L., Chai, T., Karic, A., et al. Tobacco and alcohol sales in community pharmacies: policy statements from U.S. professional pharmacy associations. J Am Pharm Assoc (2003) 54:3 (2014), 285–288.
24. Zaller, N.D., Yokell, M.A., Green, T.C., et al. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse 48:8 (2013), 590–599.
25. Jones, C.M., Lurie, P.G., Compton, W.M., Increase in Naloxone prescriptions dispensed in US retail pharmacies since 2013. Am J Public Health 106:4 (2016), 689–690.
26. Bagley, S.M., Peterson, J., Cheng, D.M., et al. Overdose education and naloxone rescue kits for family members of individuals who use opioids: characteristics, motivations, and naloxone use. Subst Abus 36:2 (2015), 149–154.
27. DeCuir-Gunby, J.T., Marshall, P.L., McCulloch, A.W., Developing and using a codebook for the analysis of interview data: an example from a professional development research project. Field Methods 23:2 (2011), 136–155.
28. MacQueen, K.M., McLellan, E., Kay, K., et al. Codebook development for team-based qualitative analysis. Field Methods 10:2 (1998), 31–36.
29. Corbin, J.M., Strauss, A.L., Basics of qualitative research: techniques and procedures for developing grounded theory. 2008, Sage Publications, Thousand Oaks, CA.
30. Wahl, K.R., Woolf, B.L., Hoch, M.A., et al. Promoting pharmacy-based referrals to the tobacco quitline: a pilot study of academic detailing administered by pharmacy students. J Pharm Pract 28:2 (2015), 162–165.
31. Nielsen, S., Menon, N., Larney, S., et al. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction 111:12 (2016), 2177–2186.
32. Murphy, A., Szumilas, M., Rowe, D., et al. Pharmacy students’ experiences in provision of community pharmacy mental health services. Can Pharm J (Ott) 147:1 (2014), 55–65.
33. Nguyen, E., Chen, T.F., O'Reilly, C.L., Evaluating the impact of direct and indirect contact on the mental health stigma of pharmacy students. Soc Psychiatry Psychiatr Epidemiol 47:7 (2012), 1087–1098.
34. O'Reilly, C.L., Bell, J.S., Chen, T.F., Consumer-led mental health education for pharmacy students. Am J Pharm Educ, 74(9), 2010, 167.
35. O'Reilly, C.L., Bell, J.S., Kelly, P.J., et al. Impact of mental health first aid training on pharmacy students’ knowledge, attitudes and self-reported behaviour: a controlled trial. Aust N Z J Psychiatry 45:7 (2011), 549–557.
36. O'Reilly, C.L., Bell, J.S., Kelly, P.J., et al. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Res Social Adm Pharm 11:3 (2015), e101–e109.
37. Thornicroft, G., Mehta, N., Clement, S., et al. Evidence for effective interventions to reduce mental-health–related stigma and discrimination. Lancet 387:10023 (2016), 1123–1132.
38. Green, T.C., Bowman, S.E., Zaller, N.D., et al. Barriers to medical provider support for prescription naloxone as overdose antidote for lay responders. Subst Use Misuse 48:7 (2013), 558–567.
39. Lim, J.K., Bratberg, J.P., Davis, C.S., et al. Prescribe to Prevent: overdose prevention and naloxone rescue kits for prescribers and pharmacists. J Addict Med 10:5 (2016), 300–308.
40. Wheeler, E., Jones, T.S., Gilbert, M.K., et al. Opioid overdose prevention programs providing naloxone to laypersons—United States, 2014. MMWR Morb Mortal Wkly Rep 64:23 (2015), 631–635.
41. Binswanger, I.A., Koester, S., Mueller, S.R., et al. Overdose education and naloxone for patients prescribed opioids in primary care: a qualitative study of primary care staff. J Gen Intern Med 30:12 (2015), 1837–1844.
42. Davis, C., Webb, D., Burris, S., Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics 41:Suppl (2013), 133–136.
43. Davis, C.S., Carr, D., Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug Alcohol Depend 157 (2015), 112–120.
44. Green, T.C., Mann, M.R., Bowman, S.E., et al. How does use of a prescription monitoring program change pharmacy practice?. J Am Pharm Assoc (2003) 53:3 (2013), 273–281.
45. Ulbrich, T.R., Dula, C.A., Green, C.G., et al. Factors influencing community pharmacists’ enrollment in a state prescription monitoring program. J Am Pharm Assoc (2003) 50:5 (2010), 588–594.
46. Davis, C.S., Burris, S., Beletsky, L., et al. Co-prescribing naloxone does not increase liability risk. Subst Abus 37:4 (2016), 498–500.